Certest biotec and bd announce collaboration on molecular diagnostic test for monkeypox

Certest biotec uses the bd max™ molecular diagnostic system open system reagent suite to develop rt-pcr detection kit zaragoza, spain and franklin lakes, n.j., june 8, 2022 /prnewswire/ -- certest biotec and bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced a collaboration to develop a molecular diagnostic test for the monkeypox virus.
BDX Ratings Summary
BDX Quant Ranking